 | TheStreet Downgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) to D-
marketbeat.com - February 27 at 7:04 AM |
 | BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 8%
americanbankingnews.com - March 4 at 9:02 PM |
 | BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
finance.yahoo.com - March 2 at 9:24 AM |
| Why BioCryst Pharmaceuticals Stock Is Popping Today
finance.yahoo.com - March 1 at 6:01 PM |
| Cowen Begins Coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX)
americanbankingnews.com - March 1 at 8:33 AM |
| Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) & Dyadic International (NASDAQ:DYAI)
americanbankingnews.com - February 27 at 4:48 PM |
| BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results, Misses Expectations By $0.09 EPS
americanbankingnews.com - February 26 at 6:10 PM |
| BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema
finance.yahoo.com - February 26 at 12:29 PM |
| BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 11.3%
americanbankingnews.com - February 25 at 10:00 PM |
| BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
finance.yahoo.com - February 25 at 8:32 PM |
|
 | BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript
msn.com - February 25 at 3:31 PM |
 | Why BioCryst Pharmaceuticals Stock Is Falling Today
fool.com - February 25 at 2:22 PM |
| BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates
msn.com - February 25 at 10:11 AM |
| BioCryst Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - February 25 at 10:11 AM |
| BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
finance.yahoo.com - February 25 at 10:11 AM |
| BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 6.5% Higher
americanbankingnews.com - February 24 at 9:16 PM |
| BioCryst Pharmaceuticals (BCRX) Set to Announce Earnings on Thursday
americanbankingnews.com - February 18 at 2:48 AM |
| BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 8%
americanbankingnews.com - February 16 at 8:22 PM |
| What Kind Of Shareholders Hold The Majority In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares?
finance.yahoo.com - February 7 at 8:48 AM |
 | BioCryst climbs after FDA approval for Rapivab in infants
seekingalpha.com - February 5 at 12:14 AM |
| BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older
finance.yahoo.com - February 3 at 8:00 AM |
 | BioCryst Pharmaceuticals Reaches Analyst Target Price
nasdaq.com - February 2 at 2:45 PM |
| The GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge
finance.yahoo.com - February 2 at 2:45 PM |
| Reddit Traders Declare ‘BioWar’ as Shorted Biotechs Soar
finance.yahoo.com - February 1 at 6:35 PM |
 | Options Surge Could Work in BioCryst's Favor Today
marketwatch.com - February 1 at 1:34 PM |
| BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo
finance.yahoo.com - January 25 at 1:47 PM |
| BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
finance.yahoo.com - January 22 at 8:52 AM |
| First Week of September 17th Options Trading For BioCryst Pharmaceuticals (BCRX)
nasdaq.com - January 15 at 6:37 PM |
| BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 9:01 AM |
| 2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started
finance.yahoo.com - December 23 at 9:31 AM |
|
| Why BioCryst Pharmaceuticals Stock Is Sinking Today
finance.yahoo.com - December 22 at 1:11 PM |
| BioCryst Provides Update on Galidesivir Program
finance.yahoo.com - December 22 at 8:10 AM |
| BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
finance.yahoo.com - December 21 at 9:30 AM |
| Is BCRX A Good Stock To Buy Now According To Hedge Funds?
finance.yahoo.com - December 18 at 11:39 PM |
| First Week of BCRX February 2021 Options Trading
nasdaq.com - December 18 at 1:33 PM |
| BioCryst Announces U.S. Availability of ORLADEYO(TM) (berotralstat) for the Treatment of Hereditary Angioedema
marketwatch.com - December 17 at 12:30 AM |
| BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema
finance.yahoo.com - December 16 at 9:29 AM |
| BioCryst to Present at JMP Securities Hematology Summit
finance.yahoo.com - December 11 at 7:24 AM |
| BioCryst Pharmaceuticals: Orladeyo Approved, Financing Overhang Removed
seekingalpha.com - December 10 at 6:27 AM |
 | Durham drugmaker secures $325M to support commercial launch
bizjournals.com - December 9 at 11:04 PM |
| BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Insiders Increased Their Holdings
finance.yahoo.com - December 9 at 8:08 AM |
| BioCryst: Time To Switch Hats? A Mid Cap Fits Now, Maybe A Large Cap?
seekingalpha.com - December 8 at 8:44 AM |
 | BioCryst's Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement
benzinga.com - December 6 at 5:07 PM |
| BioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement
finance.yahoo.com - December 6 at 5:07 PM |
| Durham drugmaker reaches huge milestone, looks ahead to $500M goal
bizjournals.com - December 4 at 5:30 PM |
| Looking Into Biocryst Pharmaceuticals's Return On Capital Employed
benzinga.com - December 4 at 5:30 PM |
| Why BioCryst Stock Is Crushing It Today
fool.com - December 4 at 5:30 PM |
| BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo
nasdaq.com - December 4 at 5:30 PM |
| BioCryst Announces FDA Approval of ORLADEYO(TM) (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
marketwatch.com - December 4 at 3:15 AM |
| FDA Approves BioCryst's Hereditary Angioedema Drug - Japan & Europe Next?
nasdaq.com - December 4 at 3:15 AM |
| BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
finance.yahoo.com - December 3 at 10:15 PM |
